Central Fatigue: Drugs That Cause It, Drugs That Treat It, and What Clinicians Look For

What Exactly Is Central Fatigue?

Central fatigue is a reduction in the brain's ability to generate and sustain the neural drive required for voluntary movement or sustained cognitive work. It differs from peripheral fatigue, which reflects depletion of substrates or accumulation of metabolites inside muscle fibers. In central fatigue, the muscles themselves may retain full contractile capacity, yet the CNS reduces its output.

The standard operational definition used in research comes from the work of Gandevia (2001), who described central fatigue as "a progressive reduction in voluntary activation of muscle during exercise," distinct from any failure at the neuromuscular junction or beyond [1].

The Neurotransmitter Hypothesis

The most studied mechanism involves serotonin and dopamine imbalance during sustained activity. When serotonin rises relative to dopamine in the brain, the perceived effort of a task increases and motivation to continue falls. A 2020 review in Frontiers in Neuroscience confirmed that manipulating the serotonin-to-dopamine ratio alters time to exhaustion in both physical and cognitive tasks [2].

Adenosine accumulation adds a second layer. Waking hours produce adenosine buildup in the basal forebrain; caffeine blocks adenosine receptors (A1 and A2A) to blunt this signal. Several fatigue-causing drugs, including opioids and certain antiepileptics, potentiate adenosinergic tone.

Neuroinflammation as a Driver

Proinflammatory cytokines, specifically interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma, act on hypothalamic circuits to produce what researchers call "sickness behavior," a conserved biological response that includes profound fatigue. This is the mechanism behind cancer-related fatigue, infection-associated fatigue, and the fatigue that follows immune-activating medications like interferon-beta.

A 2019 meta-analysis in Brain, Behavior, and Immunity (pooling data from 23 studies, N=2,406) found that serum IL-6 was significantly elevated in patients with cancer-related fatigue compared to non-fatigued cancer patients (standardized mean difference 0.41, P<0.001) [3].

Drugs That Commonly Cause Central Fatigue

A wide range of prescribed medications reduce CNS arousal, impair dopaminergic drive, or amplify inhibitory neurotransmission. Knowing which drug class is responsible guides substitution or dose adjustment.

CNS Depressants and GABAergic Agents

Benzodiazepines (diazepam, lorazepam, clonazepam) and the related Z-drugs (zolpidem, eszopiclone) produce central fatigue by potentiating GABA-A receptor activity. Patients on chronic benzodiazepines report daytime fatigue roughly twice as often as matched controls in observational data from the National Health and Nutrition Examination Survey [4].

Gabapentin and pregabalin bind the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release throughout the CNS. In the key pregabalin fibromyalgia trial (N=529), somnolence occurred in 28% and dizziness in 45% of patients at 450 mg/day versus 13% and 14% in placebo [5].

Opioids

Opioids produce fatigue through at least three pathways: direct mu-receptor sedation, hypothalamic-pituitary suppression (leading to secondary hypogonadism), and adenosinergic potentiation. Testosterone suppression from long-term opioid therapy occurs in up to 74% of men on around-the-clock opioids, according to data cited in the 2016 Endocrine Society Clinical Practice Guideline on male hypogonadism [6]. Treating opioid-induced hypogonadism with testosterone replacement frequently improves energy levels, though this must be balanced against each patient's clinical picture.

Beta-Blockers

Beta-adrenergic blockers, particularly lipophilic agents like propranolol and metoprolol that cross the blood-brain barrier, blunt norepinephrine signaling in the CNS. A Cochrane review of beta-blockers in heart failure found fatigue as an adverse effect in 3-5% more patients on beta-blockers than on placebo, a modest but consistent signal [7].

Hydrophilic agents like atenolol and bisoprolol are associated with lower CNS penetration and may produce less central fatigue, though head-to-head data comparing fatigue rates specifically are limited.

Antidepressants and Antipsychotics

Tricyclic antidepressants (TCAs) cause fatigue through antihistaminergic (H1 blockade) and anticholinergic mechanisms. Amitriptyline at doses used for neuropathic pain (10-75 mg nightly) frequently produces next-day sedation and cognitive sluggishness. Mirtazapine, with potent H1 antagonism, is one of the most sedating antidepressants at low doses (7.5-15 mg).

Atypical antipsychotics differ by receptor profile. Quetiapine carries the highest H1 affinity in its class and is used off-label as a sedative for that reason; aripiprazole has comparatively low H1 affinity and tends to produce less daytime fatigue.

Selective serotonin reuptake inhibitors (SSRIs) are a more complex case. Acutely, they may worsen fatigue through serotonergic excess; over weeks, patients with depression often see energy improve as depressive symptoms remit. The net effect depends heavily on the underlying diagnosis and the individual patient.

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) frequently cause transient fatigue, especially in the first 4-8 weeks and after dose escalations. The mechanism is not fully established but likely involves reduced caloric intake, slowed gastric emptying affecting nutrient timing, and direct GLP-1 receptor expression in the hypothalamus and brainstem. In the SURMOUNT-1 trial (N=2,539), fatigue was reported in 8.2% of patients on tirzepatide 15 mg versus 4.3% on placebo [8]. This typically resolves without dose reduction once the body adjusts to the new energy intake level.

Antiepileptics, Immunomodulators, and Hormonal Agents

Valproate, topiramate, and levetiracetam each produce fatigue through overlapping mechanisms: sodium channel inhibition, GABA potentiation, and mitochondrial effects. Topiramate in particular is associated with word-finding difficulty alongside fatigue, a profile sometimes called "Dopamax" in clinical shorthand.

Interferon-beta-1a (Avonex, Rebif), used in relapsing multiple sclerosis, causes flu-like fatigue in up to 67% of users, driven primarily by cytokine induction. Exogenous progestins (medroxyprogesterone acetate in particular) produce central sedation via neurosteroid-GABA interactions, contributing to fatigue in some contraceptive and HRT users.

Drugs and Interventions That Treat Central Fatigue

Treatment of central fatigue depends on the underlying cause. When a causative drug can be removed or substituted, that takes priority. When fatigue arises from a defined condition, disease-specific agents have the strongest evidence.

Amantadine for MS-Related Fatigue

Amantadine 100 mg twice daily remains the most commonly prescribed pharmacological treatment for multiple sclerosis fatigue. Its exact mechanism in fatigue is debated but probably involves dopaminergic and glutamatergic effects.

A Cochrane systematic review (2012, updated 2021) evaluated amantadine, modafinil, and pemoline for MS fatigue. Amantadine showed modest benefit over placebo on the Fatigue Severity Scale (FSS) in four of five included trials, though effect sizes were small and the quality of evidence rated moderate [9]. The 2019 National Multiple Sclerosis Society clinical bulletin recommends starting with 100 mg each morning and noon, avoiding late afternoon doses to prevent insomnia.

Modafinil and Armodafinil

Modafinil 200 mg once daily promotes wakefulness primarily through dopamine transporter inhibition, increasing synaptic dopamine in the prefrontal cortex and hypothalamus. It carries FDA approval for narcolepsy, shift-work sleep disorder, and obstructive sleep apnea-related sleepiness.

In MS, modafinil showed benefit in one randomized controlled trial (N=115) by Rammohan et al. (2002) but failed to separate from placebo in a later RCT by Stankoff et al. (N=115, Lancet Neurology 2005) [10]. Current evidence rates it as a second-line option behind amantadine, generally tried when amantadine provides inadequate relief.

In cancer-related fatigue, a 2021 meta-analysis in the Journal of Clinical Oncology (7 RCTs, N=1,655) found modafinil produced a statistically significant but clinically modest improvement in fatigue scores (standardized mean difference 0.27, P=0.01) primarily in patients with moderate-to-severe baseline fatigue [11].

Methylphenidate in Cancer-Related Fatigue

Methylphenidate 5-10 mg twice daily is used in palliative and oncology settings for cancer-related fatigue. A double-blind RCT published in JAMA (Moraska et al., 2010, N=148) found no benefit over placebo in the overall sample, but a prespecified subgroup analysis showed significant improvement in patients with fatigue scores above 4 on the 0-10 scale [12].

This subgroup finding supports a "threshold effect": psychostimulants may help primarily when fatigue is moderate to severe rather than mild.

Hormone Optimization

Testosterone deficiency (total testosterone below 300 ng/dL in men, per the 2018 Endocrine Society guidelines) produces fatigue, reduced motivation, and poor concentration, symptoms that overlap considerably with primary CNS fatigue syndromes [6]. Testosterone replacement therapy (TRT) in men with confirmed hypogonadism reliably improves energy scores. In the Testosterone Trials (TTrials, N=790 men aged 65+), the energy sub-study found a statistically significant but small improvement in self-reported energy with testosterone gel at 12 months [13].

Thyroid optimization matters equally. Undiagnosed hypothyroidism is among the most common correctable causes of fatigue presenting to primary care. The American Thyroid Association's 2014 guidelines recommend targeting TSH between 0.5 and 2.5 mIU/L when treating hypothyroid patients with persistent fatigue on standard levothyroxine therapy.

Exercise as Neurobiological Treatment

Aerobic exercise reduces central fatigue through multiple pathways: it increases brain-derived neurotrophic factor (BDNF), improves hypothalamic-pituitary-adrenal axis regulation, and lowers systemic inflammatory cytokines. This is not a soft lifestyle recommendation.

A 2022 Cochrane review of exercise for MS fatigue (36 RCTs, N=2,189) found moderate-certainty evidence that aerobic exercise at 60-70% of maximum heart rate for 30 minutes, three times per week, reduced FSS scores by a mean of 0.55 points (95% CI 0.33 to 0.78) [14].

How Central Fatigue Differs Across Specific Conditions

Multiple Sclerosis

MS fatigue is driven by demyelination-related slowing of neural conduction, inflammatory cytokines released during relapses, and secondary factors including sleep disruption, depression, and heat sensitivity (Uhthoff's phenomenon). The 2021 MS Society Clinical Bulletin states: "Fatigue is the most common symptom in MS, reported by 75-95% of patients, and the symptom most likely to interfere with daily functioning" [9].

Cancer-Related Fatigue

Cancer-related fatigue (CRF) affects nearly all patients receiving cytotoxic chemotherapy and up to 80% of those on radiation therapy. The National Comprehensive Cancer Network (NCCN) 2023 Clinical Practice Guidelines for Cancer-Related Fatigue recommend screening all cancer patients at every visit using a 0-10 numeric scale, with scores of 4 or above triggering a full evaluation [15].

Post-COVID and Long COVID

Persistent fatigue appears in an estimated 10-35% of people beyond 12 weeks after acute SARS-CoV-2 infection, according to a systematic review in The Lancet (2023, N=54 studies) [16]. The pathophysiology involves neuroinflammation, dysautonomia, mitochondrial dysfunction, and in some patients, reactivation of latent viruses including Epstein-Barr. No drug has yet received FDA approval specifically for long COVID fatigue, making it one of the more challenging management problems in current practice.

Chronic Kidney Disease and Dialysis

Fatigue in CKD is partly central (uremic toxins crossing the blood-brain barrier, anemia-driven cerebral hypoxia) and partly peripheral. Correction of renal anemia with erythropoiesis-stimulating agents reduces fatigue scores, but residual central fatigue from uremic neurotoxins often persists even when hemoglobin normalizes.

Diagnosis: What Gets Measured and How

A practical clinical framework for central fatigue evaluation follows this sequence:

Step 1. Rule out peripheral causes first. Order CBC, CMP, TSH, free T4, fasting glucose, HbA1c, ferritin, vitamin B12, and 25-OH vitamin D. These basic labs identify anemia, hypothyroidism, diabetes, iron deficiency, and nutritional deficiencies, all of which can masquerade as central fatigue.

Step 2. Assess for hypogonadism. In men: total testosterone (8-10 AM draw), LH, FSH. In women of reproductive age: estradiol, LH, FSH on day 2-3 of the cycle. In peri- and postmenopausal women: FSH and clinical symptom inventory.

Step 3. Screen for sleep disorders. The Epworth Sleepiness Scale (ESS) and STOP-BANG questionnaire take under five minutes. Obstructive sleep apnea is underdiagnosed and produces central fatigue through intermittent hypoxia and sleep fragmentation.

Step 4. Validated fatigue instruments. The Fatigue Severity Scale (FSS, 9 items, scored 1-7) and the Multidimensional Fatigue Inventory (MFI-20) distinguish central fatigue domains (reduced motivation, reduced activity, mental fatigue) from general tiredness.

Step 5. Drug reconciliation. Review every prescription and over-the-counter drug for CNS-depressant or cytokine-inducing properties. Fatigue onset that correlates temporally with a drug initiation or dose change is strong circumstantial evidence of drug causation.

When to Escalate: Red-Flag Symptoms

Not all fatigue is benign. The following features require same-week evaluation rather than watchful waiting:

• Fatigue onset within days to weeks accompanied by unintentional weight loss of more than 5% body weight over 6 months
• New focal neurological deficits (limb weakness, diplopia, dysarthria) alongside fatigue
• Fatigue with persistent low-grade fever above 37.8 C (100 F) for more than 3 weeks
• Fatigue in a patient with known malignancy showing a sudden change in pattern
• Orthostatic symptoms (dizziness on standing, syncope) combined with fatigue, which may indicate adrenal insufficiency

The Endocrine Society's 2016 Clinical Practice Guideline on adrenal insufficiency states that "unexplained fatigue and weight loss should prompt measurement of 8 AM cortisol; a level below 3 mcg/dL is highly suggestive of primary adrenal insufficiency" [17].

Practical Drug Substitutions to Reduce Central Fatigue

When a medication is the likely culprit, substitution often resolves the problem without abandoning the therapeutic goal.

| Fatigue-Causing Drug | Potential Substitution | Rationale | |---|---|---| | Amitriptyline (neuropathic pain) | Duloxetine 60 mg/day | Lower H1 affinity, similar analgesic efficacy | | Propranolol (hypertension) | Atenolol or bisoprolol | Lower CNS penetration | | Diazepam (anxiety) | Buspirone or SSRI | No GABAergic sedation | | Quetiapine (sleep) | Melatonin 0.5-3 mg | Avoids dopamine/H1 blockade | | Opioid (chronic pain, causing hypogonadism) | Buprenorphine or tapering trial | Less HPG axis suppression | | Topiramate (migraine prevention) | Valproate or propranolol | Fewer cognitive/fatigue effects for some patients |

These substitutions require clinical judgment. Patient comorbidities, prior medication trials, and the severity of the underlying condition all determine what is appropriate in any specific case.